Stoke Therapeutics, Inc.
STOKNASDAQHealthcare● Active
$29.00
$-1.01(-3.37%)
Market Cap$1.8B
P/E Ratio—
52W High$40.22
52W Low$10.635
Stoke Therapeutics, Inc. (STOK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · STOK · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.18B | $0.04B | $0.01B | $0.01B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.18B | $0.04B | $0.01B | $0.01B | $0.00B |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.09B | $0.08B | $0.08B | $0.05B |
| G&A Expenses | $0.07B | $0.05B | $0.04B | $0.04B | $0.03B |
| Total Operating Expenses | $0.21B | $0.14B | $0.12B | $0.12B | $0.09B |
| Operating Income | ($0.02B) | ($0.10B) | ($0.11B) | ($0.10B) | ($0.09B) |
| Operating Margin %(computed) | -11.16% | -277.31% | — | -841.24% | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.09B) | ($0.10B) | ($0.10B) | ($0.09B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.09B) | ($0.10B) | ($0.10B) | ($0.09B) |
| Net Margin %(computed) | -3.73% | -243.42% | — | -814.73% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 |
| Wtd Avg Shares | 0.06B | 0.05B | 0.04B | 0.04B | 0.04B |
| EBITDA | ($0.02B) | ($0.10B) | ($0.11B) | ($0.10B) | ($0.09B) |
| EBITDA Margin %(computed) | -10.20% | -271.36% | — | -828.78% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Stoke Therapeutics, Inc. data
About Stoke Therapeutics, Inc. (STOK) Income Statement
Stoke Therapeutics, Inc. (STOK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, STOK reported revenue of $0.18B, gross profit of $0.18B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -3.73%.
Frequently asked questions
STOK · 4 questionsStoke Therapeutics, Inc. (STOK) reported revenue of $0.18B for 2025, up 404.5% year-over-year.
STOK revenueSTOK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08